Just like two unlikely friends who turn out to have nothing in common, multiple sclerosis (MS) and breast cancer may not be as closely connected as previously thought. Scientists delved into numerous studies and even used genetic variants to investigate if these two conditions share a bond. The search involved observational studies that analyzed data from over 173,000 female MS patients, and Mendelian randomization studies that explored genetically predisposed MS and its association with breast cancer risk. Ultimately, the findings indicate that there is no strong evidence supporting a link between MS and breast cancer. These results provide a valuable insight for both patients and the scientific community, potentially alleviating concerns about developing breast cancer in MS patients. While the connection between these two diseases may not hold true, it’s important to continue researching other potential factors that contribute to the development of breast cancer in different populations.
BackgroundSeveral observational studies have explored the relationships between multiple sclerosis (MS) and breast cancer; however, whether an association exists remains unknown.MethodsWe conducted a meta-analysis of observational studies and Mendelian randomization (MR) based on genetic variants to identify the relationship between MS and breast cancer. The observational studies were searched from PubMed, Embase, Web of Science, and Scopus to assess the relationship between MS and breast cancer from inception to 07 Nov 2022. Moreover, we explored the association between genetically pre-disposed MS and breast cancer risk based on an MR study. The summary analysis for MS from two separate databases [International Multiple Sclerosis Genetics Consortium (IMSGC), FinnGen] and the summary analysis for breast cancer from Breast Cancer Association Consortium.ResultsFifteen cohort studies involving 173,565 female MS patients were included in this meta-analysis. The correlation between MS and breast cancer was not statistically significant [relative ratio (RR) = 1.08, 95% confidence interval (CI) = 0.99–1.17]. In the MR analysis, we did not observe causal associations of genetically determined MS with breast cancer and its subtypes from both the IMSGC and FinnGen datasets.ConclusionThe meta-analysis of observational and MR based on genetic variants does not support the correlation between MS and breast cancer.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.